AXSM Axsome Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AXSM

Price (delayed)

$213.68

Market cap

$11.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.74

Enterprise value

$11.09B

?
Relative Growth: Rel. Growth: 66
Relative Strength: Rel. Strength: 77
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 31

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop ...

Highlights
AXSM's gross profit has surged by 60% year-on-year and by 10% since the previous quarter
The revenue has soared by 57% YoY and by 10% from the previous quarter
The quick ratio has contracted by 12% YoY but it has grown by 2.4% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.axsome.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of AXSM

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
-0.46%
1 week
1.69%
1 month
-6.4%
1 year
95.34%
YTD
17%
QTD
-12.7%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$776.57M
Gross profit
$724.04M
Operating income
-$186.07M
Net income
-$191.64M
Gross margin
93.2%
Net margin
-24.7%
AXSM's gross profit has surged by 60% year-on-year and by 10% since the previous quarter
The revenue has soared by 57% YoY and by 10% from the previous quarter
Axsome Therapeutics's net margin has surged by 51% YoY and by 7% QoQ
AXSM's operating margin is up by 48% year-on-year

Price vs fundamentals

How does AXSM's price correlate with its fundamentals

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
132
P/S
14.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.28
The EPS has grown by 26% YoY
The P/B is 105% higher than the 5-year quarterly average of 64.5 and 6% higher than the last 4 quarters average of 124.0
The equity has surged by 53% since the previous quarter and by 14% year-on-year
The revenue has soared by 57% YoY and by 10% from the previous quarter
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 29.3 but 6% higher than the last 4 quarters average of 13.4

Efficiency

How efficient is Axsome Therapeutics business performance
The ROS has soared by 50% YoY and by 7% from the previous quarter
AXSM's ROA is up by 35% YoY and by 2.9% QoQ
The ROE has grown by 29% YoY
The company's return on invested capital rose by 9% YoY

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 12% more than its total liabilities
AXSM's total liabilities is up by 20% year-on-year and by 2.9% since the previous quarter
Axsome Therapeutics's total assets has increased by 19% YoY and by 7% from the previous quarter
Axsome Therapeutics's debt is 163% higher than its equity
The equity has surged by 53% since the previous quarter and by 14% year-on-year
The debt to equity has decreased by 34% QoQ and by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.